Specialty Pharmacy

NEW YORK — Two patients in Boston whom researchers had thought were cured of HIV have experienced a relapse of the infection, according to published reports.

The New York Daily News reported that the two men, who were believed cured after receiving bone marrow transplants for lymphoma, had the virus return.

NEW YORK — Institutional pharmacy PharMerica Corp. has acquired a minority stake in specialty pharmacy company Onco360, the two companies said Monday.

Onco360, which focuses on oncology services, and PharMerica called the stake "significant," and PharMerica will have the option to acquire the rest of the company over the next several years, but financial terms of the deal were not disclosed. Onco360 currently has sales of more than $100 million per year.

FOSTER CITY, Calif. — The Food and Drug Administration has approved a new drug for hepatitis C made by Gilead Sciences, the drug maker said Friday.

SILVER SPRING, Md. — The Food and Drug Administration has approved a treatment for a sexual deformity that affects men.

NORTH WALES, Pa. — Teva Pharmaceutical Industries' U.S. subsidiary has launched a generic drug for treating warts and skin lesions, the company said.

Teva Pharmaceuticals announced the launch and availability of imiquimod cream, a generic version of Medicis Pharmaceutical Corp.'s Aldara.

The drug is used to treat external genital and rectal warts, certain types of actinic keratosis and basal cell carcinoma. Various versions of the drug had sales of about $244 million in 2011, according to IMS Health.

NEW YORK — Four drug industry trade groups are suing the board of health in King County, Wash., over a local health ordinance that they say shifts the burden of sustainable disposal of unwanted drugs onto drug companies, according to published reports.

PITTSBURGH — Mylan has completed its acquisition of the injectables business of Strides Arcolab, a deal worth nearly $2 billion, the drug maker said.

Mylan said the acquisition of Agila could cost up to $1.75 billion, including a $250 million contingent consideration. As part of the acquisition, Mylan will gain full commercialization rights for most of Agila's U.S. portfolio of experimental and marketed products, including cancer drugs, as well as significant product rights in Canada, Australia, Brazil, Japan and South Korea.

NEW YORK — Compounding pharmacies that produce sterile drugs can register as outsourcing facilities and may be exempt from certain Food and Drug Administration approval requirements, according to a document published on the FDA's website.